Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Moxetumomab pasudotox-tdfk |
| Trade Name | Lumoxiti |
| Synonyms | CAT-8015 |
| Drug Descriptions |
Lumoxiti (moxetumomab pasudotox-tdfk) is an immunotoxin targeting CD22-positive tumor cells (PMID: 30030507). Lumoxiti (moxetumomab pasudotox-tdfk) is FDA approved for use in patients with relapsed or refractory hairy cell leukemia (FDA.gov). |
| DrugClasses | |
| CAS Registry Number | 1020748-57-5 |
| NCIT ID | C68819 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Moxetumomab pasudotox-tdfk | Moxetumomab pasudotox-tdfk | 0 | 0 |
| Moxetumomab pasudotox-tdfk + Rituximab | Moxetumomab pasudotox-tdfk Rituximab | 0 | 1 |